Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.36 |
| ▸ | CHKA | P35790 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.33 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 2/20 | 0.32 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8524528 | 0.78 | ALDH1A1 (0.42) | CRHR1PTPN1CHKADHFRSMN1; SMN2 | |
| SCHEMBL15346146 | 0.76 | CRHR1 (0.40) | CRHR1PTPN1CHKAPYCR1DHFR | |
| SCHEMBL23066756 | 0.76 | CRHR1 (0.46) | CRHR1PTPN1CHKAPYCR1DHFR | |
| SCHEMBL851567 | 0.75 | CHKA (0.50) | CRHR1PTPN1CHKAPYCR1DHFR | |
| SCHEMBL8001371 | 0.74 | PYCR1 (0.50) | CRHR1PTPN1CHKAPYCR1SMN1; SMN2 | |
| SCHEMBL11246200 | 0.74 | SMN1; SMN2 (0.46) | PTPN1CHKASMN1; SMN2 | |
| SCHEMBL1077214 | 0.74 | ALDH1A1 (0.43) | KDM1AKCNH2KDM1B | |
| SCHEMBL18503805 | 0.74 | CRHR1 (0.41) | CRHR1PTPN1CHKADHFRUTS2R | |
| SCHEMBL31312990 | 0.74 | CRHR1 (0.41) | CRHR1PTPN1CHKADHFRUTS2R | |
| SCHEMBL31312928 | 0.74 | CRHR1 (0.39) | CRHR1PTPN1CHKAPYCR1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339663-B1 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2338886-A2 | Naphthalene derivatives | Novartis AG (CH) | 2011-06-29 | — | — | EP | disclosed |
| US-7045533-B2 | Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout | NOVARTIS AG (CH) | 2006-05-16 | — | — | US | disclosed |
| CN-1224598-C | Naphthalene derivatives | NOVARTIS AG (CH) | 2005-10-26 | — | — | CN | disclosed |
| US-20040053890-A1 | Naphthalene derivatives | NOVARTIS AG (CH) | 2004-03-18 | — | — | US | disclosed |
| CN-1476424-A | Naphthalene derivatives | ��˹��ŵ�� | 2004-02-18 | — | — | CN | disclosed |
| EP-1339663-A2 | NAPHTHALENE DERIVATIVES | Novartis AG (CH) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042248-A2 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053890-A1 | Naphthalene derivatives | CYP1A1, SULT1E1, CYP2F1 | CRHR1 688/4885PTPN1 2600/4885CHKA 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.